Trubion Pharmaceuticals Reports $4.1m Q2 Revenue
Trubion Pharmaceuticals has posted revenue for the second quarter $4.1 million, compared to $4.5 million for the same period an year ago. For the six month ended period,
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).
Radius Health (Radius) has announced topline Phase 2 data demonstrating that in women with osteoporosis, BA058, the company’s novel PTHrP (parathyroid hormone-related protein) analog-significantly increased bone mineral density